Bayer (New Zealand)

Recent papers from Bayer (New Zealand)

1. Development and Validation of a Passive Surveillance System for Early Detection of Pepino Mosaic Virus in Commercial Greenhouse FacilitiesViruses · 2026
2. Rovadicitinib: First ApprovalDrugs · 2026
3. Etripamil: First Approval.2026
4. Aficamten: First ApprovalDrugs · 2026
5. Doxecitine and Doxribtimine: First ApprovalPediatric Drugs · 2026
6. Bevifibatide: First ApprovalDrugs · 2026
7. Guselkumab: Pediatric First ApprovalPediatric Drugs · 2026
8. Elinzanetant: First ApprovalDrugs · 2025
9. Identifying and integrating consumer-prioritised topics and outcomes in clinical practice guidelines on managing kidney stonesBMC Nephrology · 2025
10. Revakinagene Taroretcel: First ApprovalMolecular Diagnosis & Therapy · 2025
11. Zilucoplan: First ApprovalDrugs · 2023
12. Nedosiran: First ApprovalDrugs · 2023
13. Lotilaner Ophthalmic Solution 0.25%: First ApprovalDrugs · 2023
14. Ritlecitinib: First ApprovalDrugs · 2023
15. Mangere to mainstream – the story of a perennial ryegrass ecotype, a determined farmer, and a progressive seed companyNew Zealand Journal of Agricultural Research · 2023
16. Zavegepant: First ApprovalDrugs · 2023
17. Efanesoctocog Alfa: First ApprovalDrugs · 2023
18. Elacestrant: First ApprovalDrugs · 2023
19. Sparsentan: First ApprovalDrugs · 2023
20. Nadofaragene Firadenovec: First ApprovalDrugs · 2023